Sugi Predict

Sugi Predict / Compounds / SCHEMBL4470153

SCHEMBL4470153

SCHEMBL4470153

COc1ccc(C(=O)c2cccc([N+](=O)[O-])c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.67
▸ ALDH1A1 P00352 5/20 0.67
▸ NPC1 O15118 1/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.65
▸ MAPK1 P28482 2/20 0.61
▸ HTT P42858 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ LMNA P02545 6/20 0.60
▸ RAF1 P04049 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ GFER P55789 1/20 0.60
▸ PAX8 Q06710 1/20 0.60
▸ NCOA1 Q15788 1/20 0.60
▸ NCOA3 Q9Y6Q9 1/20 0.60
▸ PKM P14618 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ CES2 O00748 1/20 0.57
▸ CES1 P23141 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31067505 1.00 MAPT (0.67) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27553472 0.91 MAPT (0.58) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7789143 0.90 MAPT (0.64) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL12350151 0.88 CES2 (0.71) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10939515 0.88 SRD5A2 (0.63) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL728795 0.86 MAPK1 (0.62) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7911565 0.85 MEN1 (0.64) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7787638 0.85 MAPT (0.64) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7789171 0.85 MEN1 (0.55) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3234327 0.84 CES2 (0.68) MAPTALDH1A1MAPK1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
US-12162838-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-12-10 — — US disclosed
US-12116346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-10-15 — — US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-6329405-B1 AS ILEAL BILE ACID TRANSPORTER INHIBITOR, FOR THERAPY OF HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 2001-12-11 — — US disclosed
CN-1287117-A Cyclobutene derivatives, preparation method and therapeutic use thereof SANKYO CO (JP) 2001-03-14 — — CN disclosed
EP-1070703-A1 Cyclobutene derivatives Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 — — EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 — — EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 — — WO disclosed
EP-0315140-B1 Non-linear optical device HITACHI LTD (JP) 1995-08-23 — — EP disclosed
US-5176854-A Xanthone Derivatives HITACHI, LTD. (JP) 1993-01-05 — — US disclosed
US-4175945-A PLANT GROWTH REGULATORS FOR TABACCO ROHM AND HAAS COMPANY (US) 1979-11-27 — — US disclosed
US-4120687-A CONTROLLING GROWTH OF TOBACCO SUCKERS MEISINGER ROBERT H 1978-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116346-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 MAPT 2685/4885ALDH1A1 1425/4885NPC1 555/4885
US-12162838-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885NPC1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.